Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
76.1M
-
Shares change
-
-3.21M
-
Total reported value, excl. options
-
$911M
-
Value change
-
-$39.6M
-
Put/Call ratio
-
0.79
-
Number of buys
-
71
-
Number of sells
-
-92
-
Price
-
$11.97
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2021
230 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2021.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.1M shares
of 295M outstanding shares and own 25.84% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (10.3M shares), BlackRock Inc. (9.78M shares), VANGUARD GROUP INC (9.11M shares), STATE STREET CORP (5.99M shares), CREDIT SUISSE AG/ (3.6M shares), JPMORGAN CHASE & CO (3.28M shares), DIMENSIONAL FUND ADVISORS LP (3.01M shares), GEODE CAPITAL MANAGEMENT, LLC (2.06M shares), GOLDMAN SACHS GROUP INC (1.55M shares), and NORTHERN TRUST CORP (1.49M shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.